Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue
Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving milestones across multiple indications. The post Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue appeared first on GEN - Genetic Engineering and Biotechnology News .
Merck & Co. has entered into a collaboration deal with SciBrunch Therapeutics to develop, manufacture, and commercialize SciBrunch's preclinical oral precision cancer candidate, SPR2015. This collaboration could potentially generate up to $2.13 billion for SciBrunch. SPR2015 is a KRAS G12D (ON) inhibitor, which is a mutation found in various forms of cancer including colorectal cancer, non-small cell lung cancer, and pancreatic ductal adenocarcinoma.
The mutation leaves KRAS active and continuously signaling for cell proliferation and survival. Preclinical studies have shown that SPR2015 has nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines while maintaining good selectivity over KRAS wildtype cells. In a head-to-head mouse study, SPR2015 demonstrated superior efficacy in CRC xenograft models compared to another unspecified G12D (ON) inhibitor. Merck and SciBrunch did not provide further details on the specifics of the collaboration.
Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
